Lederglib

Lederglib Brand names, Lederglib Analogs

Lederglib Brand Names Mixture

No information avaliable

Lederglib Chemical_Formula

C₂₃H₂₈ClN₃O₅S

Lederglib RX_link

http://www.rxlist.com/cgi/generic/glybur.htm

Lederglib fda sheet

Lederglib msds (material safety sheet)

Lederglib MSDS

Lederglib Synthesis Reference

Weber et al., U.S. Pat. 3,454,635 (1969)

Lederglib Molecular Weight

494.004 g/mol

Lederglib Melting Point

169-170^oC

Lederglib H₂O Solubility

4 mg/L

Lederglib State

Solid

Lederglib LogP

4.85

Lederglib Dosage Forms

Tablet (1.25 mg, 2.5 mg, 5 mg)

Lederglib Indication

Indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.

Lederglib Pharmacology

Glyburide, a second-generation sulfonylurea antidiabetic agent, appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glyburide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glyburide produces a mild diuresis by enhancement of renal free water clearance. Glyburide is twice as potent as the related second-generation agent glipizide.

Lederglib Absorption

Significant absorption within 1 hour and peak plasma levels are reached within 4 hours.

Lederglib side effects and Toxicity

Oral rat LD₅₀: > 20,000 mg/kg. Oral mouse LD₅₀: 3250 mg/kg.

Lederglib Patient Information

Patients should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose.

The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure also should be explained.

Lederglib Organisms Affected

Humans and other mammals